BTMD · biote Corp.
Price & Indicators
Up next
Metrics snapshot
Useful current figures from the complete screener profile.
AI Brief
Q2 FY26 earnings call · Aug 5, 2026TL;DR. Biote reported Q2 revenue down 9.5% to $44.2M and cut full-year guidance to above $175M (from above $190M) and adjusted EBITDA above $25M (from above $38M), citing recall-driven procedure revenue declines, while highlighting resolved supply, normalized Asteria Health production, and expected sequential procedure improvement in 2H.
- + Q2 cash balance rebuilt to $11.2M from $5.3M at March 31, 2026.
- + Management expects sequential procedure revenue improvement in both Q3 and Q4 2026.
- + Legal expense expected to decline after recent resolution of outstanding legal matters.
- − Full-year 2026 adjusted EBITDA guidance cut to above $25M from above $38M.
- − Gross margin compressed to 65.4% from 71.6% due to recall-related costs.
- − Q2 swung to net loss of $7.4M (diluted LPS of $0.23) vs. net income of $3.9M ($0.10 EPS) a year ago.
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Strong SellIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Adjusted EBITDA non-GAAP | 5.56M | Three Months Ended June 30 filing | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Medical Care Facilities — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
BTMD
this stock
biote Corp.
|
$44.55M | -55.8% | -2.5% | 12.4 | 3.6% |
|
HCA
HCA Healthcare, Inc.
|
$96.64B | -8.6% | +7.1% | 15.0 | 2.9% |
|
FSNUY
Fresenius SE & Co. KGaA
|
$29.92B | -13.3% | — | — | 0.0% |
|
THC
Tenet Healthcare Corp
|
$20.91B | +30.1% | +0.9% | 10.0 | 2.5% |
|
EHC
Encompass Health Corp
|
$12.18B | +12.9% | +10.5% | 20.1 | 3.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| BTMD | -5.7% | -25.8% | -35.8% | -5.0% | -55.8% |
| SPY | -0.2% | -0.5% | +12.2% | +0.9% | +12.9% |
| vs SPY | -5.5% | -25.4% | -47.9% | -5.9% | -68.6% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.